期刊文献+

Determination of cilostazol and its active metabolite 3,4-dehydro cilostazol from small plasma volume by UPLC-MS/MS 被引量:2

Determination of cilostazol and its active metabolite 3,4-dehydro cilostazol from small plasma volume by UPLC-MS/MS
下载PDF
导出
摘要 A simple,rapid and sensitive ultra performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS) method has been developed for the simultaneous determination of cilostazol and its pharmacologically active metabolite 3,4-dehydro cilostazol in human plasma using deuterated analogs as internal standards(ISs).Plasma samples were prepared using solid phase extraction and chromatographic separation was performed on UPLC BEH C18(50 mm × 2.1 mm.1.7 μm) column.The method was established over a concentration range of 0.5-1000 ng/mL for cilostazol and 0.5-500 ng/mL for 3.4-dehydro cilostazol.Intra- and inter-batch precision(%CV) and accuracy for the analytes were found within 0.93-1.88 and 98.8-101.7% for cilostazol and 0.91-2.79 and 98.0-102.7% for the metabolite respectively.The assay recovery was within 95-97% for both the analytes and internal standards.The method was successfully applied to support a bioequivalence study of 100 mg cilostazol in30 healthy subjects. A simple,rapid and sensitive ultra performance liquid chromatography-tandem mass spectrometry(UPLC-MS/MS) method has been developed for the simultaneous determination of cilostazol and its pharmacologically active metabolite 3,4-dehydro cilostazol in human plasma using deuterated analogs as internal standards(ISs).Plasma samples were prepared using solid phase extraction and chromatographic separation was performed on UPLC BEH C18(50 mm × 2.1 mm.1.7 μm) column.The method was established over a concentration range of 0.5-1000 ng/mL for cilostazol and 0.5-500 ng/mL for 3.4-dehydro cilostazol.Intra- and inter-batch precision(%CV) and accuracy for the analytes were found within 0.93-1.88 and 98.8-101.7% for cilostazol and 0.91-2.79 and 98.0-102.7% for the metabolite respectively.The assay recovery was within 95-97% for both the analytes and internal standards.The method was successfully applied to support a bioequivalence study of 100 mg cilostazol in30 healthy subjects.
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS 2015年第1期1-11,共11页 药物分析学报(英文版)
关键词 Cilostazol 3 4-dehydro cilostazol UPLC-MS/MS Sensitive High throughput Cilostazol 3,4-dehydro cilostazol UPLC-MS/MS Sensitive High throughput
  • 相关文献

参考文献23

  • 1US Department of Health and Human Services, Food and Drug Administration. NME Drug and New Biological Approval in 1999. Available from: (http://www.fda.gov/ ... lhowdrugsaredevelopedandap proved/drugandbiologicapprova1reports/ucm081686.htrn) (Last accessed April, 2014). 被引量:1
  • 2Z.A. Al-Qudab, A.E. Hassan, A.L. Qureshi, Cilostazol in patients with ischemic stroke, Expert. Opin. Pharmacother. 12 (2011) 1305- 1315. 被引量:1
  • 3Y. Liu, Y. Shaku, J. Kambayashi, Phosphodi Esterases as Drug Targets, in: S.H. Francis, M. Conti, M.D. Houslay (Eds.), Hand-book of Experimental Pharmacology, Springer-Verlag, Berlin, Germany, 2011, p. 211. 被引量:1
  • 4Y. Liu, Y. Shaku, M. Yoshitak, et al., Cilostazol (Pletal?): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake, Cardiovasc. Drug Rev. 19 (2001) 369-386. 被引量:1
  • 5M. Hiratsuka, Y. Hinai, T. Sasaki, et al., Characterization of human cytochrome P4S0 enzymes involved in the metabolism of cilostazol, Drug Metab. Dispos. 3S (2007) 1730-1732. 被引量:1
  • 6H. Akiyama, S. Kudo, T. Shimizu, The metabolism of a new antithrombotic and vasodilating agent, cilostazol, in rat, dog and man, Arzneimittelforschung 35 (1985) 1133-1140. 被引量:1
  • 7H. Akiyama, S. Kudo, M. Odomi, et al., High-performance liquid chromatographic procedure for the determination of a new antith?rombotic and vasodilating agent, cilostazol, in human plasma, J. Chromatogr. 338 (1985) 456-459. 被引量:1
  • 8S.L. Bramer, P.N.V. Tata, S.S. Vengurlekar, et al., Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LCIMSIMS, J. Pharm. Biomed. Anal. 26 (2001) 637-650. 被引量:1
  • 9CJ. Fu, P.N.V. Tata, K. Okada, et al., Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatography, J. Chromatogr. B 728 (1999) 251-262. 被引量:1
  • 10R.V.S. Nirogi, V.N. Kandikere, M. Shukla, et al., Simultaneous quantification of cilostazol and its primary metabolite 3,4-dehydroci?lostazol in human plasma by rapid liquid chromatography/tandem mass spectrometry, Anal. Bioanal. Chern. 384 (2006) 780-790. 被引量:1

同被引文献18

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部